Published in Cancer Weekly, February 10th, 1997
Pharmos scientists designed and developed the compounds internally. This patent allowance defines broad therapeutic applications for the use of charged derivatives of steroid hormone analogs and antagonists in the treatment of cancer and inflammation.
The allowed patent is based on preclinical data demonstrating the potential superior therapeutic and side effect profile of these novel pharmaceuticals compared to conventional...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.